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According to the World Cancer Report statistics provided by WHO, colorectal cancer (CRC) is one of the 
most aggressive and lethal types of cancer, standing on the top five ranking. The therapeutic efficacy of 
many anti-cancer drugs is limited by their poor penetration into tumor tissue and their adverse effects on 
healthy cells. Nano/microcarriers carriers stand as good candidates as transport means where bioactives 
for diagnosis, treatment and/or prophylaxis could be entrapped, or platforms where ligands, receptors or 
therapeutic agents could be anchored. Inverse microemulsion (IM) method is reported for preparing 
monodispersed phenetyl isothiocyanate (PEITC) loaded chitosan coated citrus pectin particles, which 
posteriorly were analyzed with respect to their morphology and pH stimuli responsiveness. Crosslinked 
unloaded and ibuprofen loaded chitosan:citrus pectin microspheres were prepared by a spray drying 
method. The parameters studied were the surface morphology and loading capacity. Complementarily, 
impregnation by supercritical CO2 was performed in spray dried unloaded particles as an alternative 
encapsulation method, comparing the effects of slow and rapid depressurization in encapsulation 
efficiency. The particles synthesized by IM presented a regular surface, spheroid shape and nearly uniform 
particle size distribution. The pH stimuli response was confirmed with particle size increasing or 
decreasing according to the medium acidification or alkalization.  It was found that the size of the particles 
is directly proportional to the number of days of crosslinking reaction. Spray dried unloaded particles 
showed a spheroid shape and smooth surface with small concavities; while ibuprofen loaded particles 
presented a highly irregular surface and shape with a collapsed surface. This fact may be due to ionic 
interactions between drug and chitosan.  The loading of 89% rate was very positive, and proved that this is 
a great method for encapsulating actives. Encapsulation by impregnation showed less than 1% of 
encapsulation efficiency, both for slow and rapid depressurization. 
Key words: colorectal cancer, polymeric particles, natural extracts, supercritical CO2, spray drying, 























De acordo com as estatísticas da OMS (World Cancer Report) o cancro colorectal é um dos mais 
agressivos e letais, posicionando-se entre os cinco primeiros, com 694.000 só em 2012.  A eficácia 
terapêutica de muitas drogas anticancerígenas é limitada pela fraca penetração no tecido tumoral e pelos 
efeitos adversos nas células saudáveis. Nano/micropartículas são uma boa alternativa como meio de 
transporte aonde agentes bioactivos para diagnóstico, tratamento e/ou profilaxia podem ser encapsulados, 
ou plataformas aonde ligandos, receptores ou agentes terapêuticos possam ser ancorados. O método de 
microemulsão inversa foi usado para a preparação de partículas monodispersas de pectina cítrica 
recobertas com quitosano, carregadas com PEITC, que depois foram posteriormente analisadas quanto à 
sua morfologia e resposta às mudanças de pH. Microesferas reticuladas de quitosano:pectina cítrica foram 
preparadas por spray drying. Os parâmetros estudados foram a morfologia da superfície e capacidade de 
encapsulação. Complementarmente, foi feita uma impregnação por CO2 supercrítico nas partículas vazias 
produzidas por spray drying, comparando os efeitos da despressurização rápida e lenta na eficiência da 
encapsulação. As partículas sintetizadas por microemulsão inversa apresentaram uma superfície regular, 
forma esférica e uma distribuição de tamanho uniforme. A resposta à variação pH foi confirmada com o 
tamanho da parícula a aumentar e a diminuir consoante com a acidificação ou alcalinização do meio. Foi 
demonstrado que o tamanho das partículas é directamente proporcional ao número de dias de reacção de 
cruzamento. As partículas descarregadas do spray drying apresentaram uma forma esferóide com 
superfície lisa com pequenas concavidades, enquanto que as partículas carregadas mostraram um 
superfície e forma irregulares com uma superfície colapsada. Isto deve-se a interacções entre a droga e o 
quitosano. Uma percentagem, muito positiva, de encapsulamento de 89%, foi conseguida provando que 
esta é uma forma muito eficaz de encapsular activos. A encapsulação por impregnação foi de menos de 
1%, tanto para a despressurização lenta como para a rápida. 
Palavras-chave: cancro colon-rectal, partículas poliméricas, extractos naturais, CO2supercrítico, spray 
drying, microemulsão inversa  
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1.1 – HISTORICAL AND SOCIOCULTURAL FRAMEWORK 
As the human race evolves in knowledge and technologies, lifestyle and general habits, tends to follow 
these changes. So there are, for each stage of human history, some aspects that characterize that particular 
age. For many scholars, 20
th
 century shall be known as the Cancer´s Century. Ever since Hippocrates and 
his disciples had first described cancer cells agglomerates as carcinos and carcinoma (from Greek 
Karkinos, meaning crab), because of the structural similarity of the cell projections that seems to emerge 
from tumours as crab´s claws (Taylor et al, 2015), to this day, cancer has, certainly, made millions or even 
billions of victims. According to Sontag (Sontag, 1978), cancer was perceived, not like other diseases, but 
like a malediction that could even represent banishment of the affected person from social interaction. It 
was known as the disease that “does not knock before it enters”, and, unlike other diseases, it did not seem 
to be dependent from economic conditions of the patients. The very word “cancer” was, for many decades, 
filled with stigma, and it was, literally a synonym for death. It distinguished itself from other diseases as 
there was no ultimate and absolute solution, a universal treatment, a cure, as penicillin was for 
tuberculosis, the disease that astonished the civilization for a long period of time (Diamandopoulus, 1996). 
Table 1.1 presents a small review of historical society views about that disease, along with some advances 
in the field of psycho-oncology. 
 
Table 1.1 - Historical perspective about society attitudes with regard to cancer patients, and development of psycho-oncology in 




Prevailing attitude was that cancer equals death 
Diagnosis never revealed to patient 
Fatalistic acceptance of diagnosis by doctor and family 
1900-20s American Cancer Society formed to fight fatalism and educate public that 
early treatment by surgery could be curative 
1930s National Cancer Institute formed to seek a cure for cancer (1937) 
1950s 
  
Combined modalities lead to increased survival in Hodgkin's disease, acute 
lymphoblastic leukemia (ALL), and childhood tumours 
First studies of psychological response to cancer reported 
1960-70s Debate about telling or not telling diagnosis; change to revealing the 




Psychosomatic research in psychiatry led to focus on studies of psychological 




Prevalence studies of psychiatric and psychological sequelae in cancer 
Psycho-oncology units develop in larger cancer centers 
Education of public about lifestyle and cancer prevention; behavioral research 




Health-related Quality of Life assessment was accepted as an outcome 
measure in clinical trials 
Intervention studies undertaken to impact quality of life and reduce distress 
Development of psychoneuroimmunology and exploration of its relevance to 
cancer and risk/ survival 
2000 Development of standards for psychosocial care and clinical practice 
guidelines 
 
At present, cancer patients have rid themselves of that stigma, for the advances of science and technology 
have demystified the concept that cancer means death. Especially for the last ten years, the scientific 
research about cancer has seen widespread growth, and each day more and more drugs and treatment 
option have been arising from that tireless effort (American Cancer Society, 2016a). Although that subject 
has come to occupy a prime position in the field of health related sciences and industries, the challenge is 
far from being won. Today, cancer is a constant reminder of the impotence of the human being when it 
comes to control illness and death. 
1.2 - COLORECTAL CANCER  
According to the statistics provided by GLOBOCAN  in their last worldwide cancer report, just in 2012, 
the most recent year for which international estimates are available, there has been 14 million new cases 
and 8.2 million of people dying from some form of cancer (Stimpfel and Virant-Klun, 2016). Of those, 
Colorectal cancer (CRC) is one of the most aggressive and deadly cancer types, standing on the top five 
rank, with 694 000 deaths, just in 2012 (Ferlay et al, 2014). It is the third most common type of cancer in 
men and the second in women, with almost 55% of the cases occurring in most developed countries, 
although, in terms of incidence/mortality ratio, mortality is higher in less developed countries (Siegel et al, 
2015). Figure 1.1 and Table 1.2 represent the main results of the last World´s Cancer Statisctics report, 




Figure 1.1- Graphic describing cancer incidence (left) and mortality (right) worldwide. Source Globocan (IARC), 2012. 
Table 1.2- 2012´s worldwide statistics of incidence and mortality of CRC, according to geography and gender. Source: Globocan 
(IARC), 2012. 
 
The colon consists of four parts: ascending, transverse, descending and sigmoid colon. It measures about 
1.5 meters and it has a retention time ranging from 3 to 10h. It extracts water and salts from solid wastes 
before they are eliminated from the body. The parts of the colon are located either in the abdominal cavity 
or behind it, in retro peritoneum. The ascending and descending colon and rectum are retroperitoneal, 
while transverse colon is intra peritoneal (Sreelatha and Brahma, 2013).  
The definition of CRC covers all neoplasia that start in any part of the large intestine or rectum, and it can 
be named according to its location (colon or rectum). CRC is almost always preceded by an adenomatous 
polyp, that is, a projection of the inner lining towards the lumen. These polyps are, by a large majority, 
benign tumours, with only a minority developing cancer over time (Boyle and Lang, 2000a). To be 
considered a malignant tumour, it has to penetrate through muscularis mucosae into submocosa (Aaltonen 
& Hamilton 2000). According to Langman & Boyle (2000), CRC relies heavily on environmental factors, 
since the incidence of CRC varies in space and time, “groups of migrants quickly lose the risk associated 
with their original home community and acquire the patterns of the new community” (Boyle and Lang, 
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2000b). The individual risk of developing CRC is dependent of lifestyle habits and genetic predisposition, 
and also in increasing age (National Collaborating Centre for Cancer, 2011). 
 
Figure 1.2 - 2012´s Worlwide statistics of incidence and mortality of CRC, according to geography and gender. Source 
GLOBOCAN 2012 - Colorectal cancer statistics. 
As we can see on Figure 1.2, although the incidence of CRC is higher in more developed countries, these 
countries are more successful in treating and defeating CRC. According to the American Cancer Society, 
surgery still is the first approach most of the time, the type of surgery being dependent on stage, 
localization, size and other tumour related factors. Other treatment options can be considered, especially 
when surgery is no longer an option, or when is not possible to remove the entire tumour or all tumour 
metastasis. These options include ablation, when the tumour is destroyed without removing it, and 
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embolization that consists in blocking the blood flow to the cancer cell agglomerate (American Cancer 
Society, 2016b). Radiotherapy and chemotherapy are normally used as adjuvant or neo-adjuvant therapy, 
or in order to induce and/or consolidate remissions (Ayanian el al, 2003). It is also very common to 
combine chemo and radiotherapy as chemotherapy makes cancer cells more sensitive to the radiation; this 
procedure is called chemoradiation (Goldberg et al, 2011). Although chemo and radiotherapy can be very 
effective, the side effects are, sometimes, nearly as aggressive as the cancer itself. The side effects are not 
very predictable as they tend to be different in occurrence and in proportion for each person; however 
some side effects like hair loss, diarrhoea, persistent fatigue, faintness and drowsiness seem to be 
problems shared by every patient (National Cancer Institute (2015). These reactions are due to the fact 
that those treatments are not very selective to the type of cells that are killed, and, despite the fact that 
cancer cells are more vulnerable to them, normal cells are also killed during the treatment, as these 
systems do not distinguish between fast-growing cancer cells and other types of fast-growing cells, such 
as blood cells, skin cells and the cells inside the stomach (Angelis, C. D. 2008a). 
1.3 - TARGETED THERAPY 
Angelis, compared the experience of many patients with cancer to an ancient Greek mythology story that 
tells of a titan Angelis (2008), Prometheus, that for having stolen fire and handed as a gift to the man kind, 
was punished by Zeus to be chained alongside to the top of the Mont Caucasus and to have his liver eaten 
by an eagle (Angelis, C. D. 2008b). As Prometheus was immortal his organ regenerates itself constantly, 
and so the destructive cycle restarted day after day. This myth is an accurate analogy to what happens 
many times with cancer cells: just when it is thought that they are all destroyed, one remaining group of 
those starts to grow again. This recurrence relies, most of the times, on the low specificity of the 
treatment. The introduction of chemo and radiotherapy in cancer treatment resulted in an immediate, 
significant and undeniable impact towards cancer cure and reduction of cancer related mortality, and the 
constant research in this field lead to the development of new agents and therapies with new, but non-
selective mechanisms of action (Chabner and Roberts 2005). Conventional chemotherapy associated 
toxicity, due to the indiscriminate killing of healthy cells, as well as the development of multidrug 
resistance due to numerous complex mechanisms, supports the need to find new effective targeted 
treatments based on the changes in the molecular biology of the tumour cells (Pérez-Herrero and 
Fernández-Medarde, 2015). So it was clear that new approaches would be necessary, if better results were 
expected, and with the rapid increase in knowledge and technology development in the areas  of molecular 
biology, biotechnology, nanotechnology and other related sciences, we soon came to learn more about the 
molecular and structural differences between normal and cancer cells, and exploit that knowledge in order 
to bring to the next level the cancer treatment options, namely by targeting those cells based on specific 
biomarkers. The aim is now to improve the uptake of the anticancer agent by malignant cells, without 
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affecting normal tissue, by “focusing on unique features of the tumour microenvironment, such as leaky 
vasculature, overexpressed cell surface receptors, and intratumoural pH differences, as well as features of 
the cell uptake process, such as endosomal pH” (Alexander-Bryant et al, 2013).  The development of 
molecularly targeted cancer therapeutics such as anti-angiogenic agents, proteasome inhibitors and growth 
factor receptor inhibitors have contributed to advances in the treatment, by making it possible to 
selectively target the physiology of cancer cells. (Pathania et al., 2009). 
1.4 - NANOTECHNOLOGY 
The rise of nanotechnology has led to major advances in the field of targeted therapeutics and tumour 
targeted drug delivery, enabling more effective drug design and development, which has revolutionized 
cancer therapy.  
About half a century after the physicist Richard Feyman´s, considered the father of the nanotechnology, 
most famous lecture “There's plenty of room at the bottom”, in which he prophesied about the rise of 
small carriers that would be able to mimic biological systems through manipulation and control of small 
atoms and molecules  (Gazit and Mitraki, 2007), nanotechnology has developed amazingly and become 
one of the most promising study fields of the new century, with practical application in many scientific 
areas. In all, over 4000 calls for proposals were published by the end of 2014, and a total of 1381 
nanotechnology based formulations were registered for clinical trials (Wicki et al., 2015a). Expressions 
such as nanotherapy, nanomedicine and nanotheragnosis are now synonymous of innovation and 
efficiency. The study of artificial or natural biocompatible materials, with low toxicity and low 
immunogenicity, and advances in cancer research lead to the development carriers that can transport 
anticancer agents specifically to the cancer cells (Pala et al, 2014a). Nano/microparticulate carriers can be 
made from several organic and inorganic materials such as non-degradable and biodegradable polymers, 
lipids (liposomes, nanoemulsions, and solid-lipid nanoparticles) self-assembling amphiphilic molecules, 
dendrimers, metal, and inorganic semiconductor nanocrystals (Couvreur and Vauthier, 2006). These small 
carriers stand as good candidates for transport means where agents of interest can be entrapped for 
diagnosis, treatment and/or prophylaxis, platforms where ligands and/or receptors could be anchored and 
used as tools that can be used in hyperthermia, phototherapy and magnetic therapy (Brigger et al, 2012). 
The increasing knowledge of tumour specific characteristics has been a strong allied in the development of 
nanotechnology for tumour targeting, by bringing to light many aspects in which tumour cells differ from 
regular healthy cells. This knowledge can be used to choose the right biomaterial, synthetize smart carriers 
and enhance targeting by functionalization with ligands and engineering particles that can respond to 
certain specific stimuli.  Nanocarriers are used to enhance the bioavailability of drugs by helping to 
overcome solubility and chemical stability problems. Paclitaxel, is an example of a drug whose poor 
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pharmacokinetic properties have been improved by the use of a nano-based therapeutic albumin-bound 
drug (Dy et al, 2014). Lipophilic agents can be enveloped inside as a mean to improve internalization and 
uptake, as the cellular membrane is an assembly of phospholipids and lipoproteins (Baek and Na, 2013). 
Besides the particles can be designed so that they can penetrate the tumour cell agglomerate, and achieve 
the central core of the tumour (Minchinton and Tannock, 2006). Drugs cleaved enzymatically (e.g., siRNA 
by RNAses in the plasma, proteins by pepsin or trypsin in the stomach) can be protected from 
biodegradation, and can have their half-life extended (Wicki et al., 2015b).  
In summary, the high tunability allowing modification of properties of the biomaterial, the ability to target 
tumour cells, the possibility of particles accumulation in tumour tissue, the ability of improvement of drug 
bioavailability and half-life, controlled drug release and several methods of triggering drug release and 
ability of entrapment of different therapeutic agents simultaneously, including imaging agents, are some of 
the main reasons that  make nano/microcarries one of the most promising tools on tumour diagnosis and 
treatment.  
Regarding this matter, two targeting strategies known as passive targeting or smart approach, and active 
targeting or targeted approach can be mentioned:  
 Passive targeting takes advantage of the fact that nanoparticles have shown to have a prolonged 
blood half-life than conventional drugs, and tend to accumulate at particular sites due to the 
balance between vascular hemodynamic forces and diffusion mechanisms (Pala et al, 2014b). 
Typically, tumour vessels are highly disorganized and dilated with a high number of pores, 
resulting in enlarged gap junctions between endothelial cells and compromised lymphatic 
drainage. The 'improvised' vascularization, creates what is called the Enhanced Permeability and 
Retention (EPR) effect, and allows migration of macromolecules into the surrounding tumour 
region and retention of those for prolonged periods. Although EPR has afforded an efficient 
strategy for anti-cancer drug design by allowing high selectivity, improved therapeutic efficacy 
and decreased toxicity (Maeda et al, 2006), it should be noted that this phenomenon is highly 
heterogeneous and there is not an established pattern, as it tend to differ from patient to patient 
and from tumour to tumour (Jain and Stylianopoulos, 2010). 
 Acording to Pala et al, “active drug targeting involves the use of a variety of affinity ligands to 
direct the binding of nanoparticles to many biological targets, largely represented by antigens that 
are differentially overexpressed both in the plasma membrane and in diseased tissue” (Pala et al, 
2014c). Active targeting concept lies on the fact that many proteins and receptors are expressed, 
overexpressed or mutated differentially by cancer cells, this biological process can be used to 
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“hit” specific tumour cells. Monoclonal antibodies, specific peptides and proteins, aptamers, and 
small-molecule drugs have been used as a means to achieve that goal (Pala et al,2014d). 
 
Figure 1.3 - Small illustration comparing the effectiveness of specif drug delivery using passive(A) or active(B) targeting. 
Retrieved from: Préat el al, 2010. 





by Novartis), an anticancer drug, to actively target a form of the enzyme tyrosine kinase, that stimulates 
uncontrolled cell growth in white blood cells. Imatinib is indicated in the treatment of Chronic Myeloid 
Leukemia (Druker et al, 2001; Lugo et al, 1990).  
1.5 – COLORECTAL CANCER TARGETING STRATEGIES 
A key aspect to be taken into account concerning colon targeting is the existence of a direct route: the 
gastrointestinal tract (GIT). The oral administration, besides being the most convenient route to reach the 
colorectal region, is the most common method of drug delivery, as it is relatively less invasive and, 
certainly, more accepted among the patients (Kurtz et al, 2003). Orally administrated formulations, aiming 
for the colon, can be designed either for local or systemic delivery. In the local delivery, the site of action 
and the site of delivery are the same, and in systemic delivery the drug will be absorbed in the colon but 
will take effect in another organ (Hua, 2015). In this case, successful colon-specific drug delivery is 
dependent on the synergistic interaction between the delivery system and the gut physiology. More 
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concretely, when using nano-based formulations, the overall performance of a colon-specific delivery 
system will be influenced by the chemistry and characteristics of the biomaterial, and on the release 
mechanism (Yang, 2008). Because of the proximity between colon and rectum (Figure 1.4), it may appear 
that rectal administration is a more appropriate, direct and logic, approach, to reach cancerous site, 
however, due to the peristaltic motion, it is difficult to patronize the distribution of the drugs administered 
by this route, and to reach ascending, transverse, and even upper descending colon, although it could be an 
option when the tumour localization is near or in the rectum. In this case, rectal formulation such as 
enemas and suppositories can be exploited (Fell,1996; Patel et al, 2012a). In order to avoid the premature 
release of the active compound in the stomach and small intestine, providing that release upon entry to the 
colon region, is required a triggering mechanism, built in the delivery system, responsive to the 
physiological changes particular to the GIT.  
 
Figure 1.4 - Schematic representation of gastrointestinal tract. Retrieved from: Visionary Health Compounding Chemist. (2011). 
According to Patel et al (2012), triggering mechanisms can be classified as follows: 
 SPECIFIC   
1. pH-sensitive natural or synthetic polymers, which will respond to pH variations of the GIT 
tract, dissolving at the pH value associated with colon environment;  
2. Microflora activated systems, which will be metabolized and/or modified in some way by 
enzymes produced by GIT microbial. 
 NON SPECIFIC - In this kind of delivery system the aim is not to trigger the delivery, but is to 
take advantage of cancer´s particular characteristics to release the drug, preventing premature 
release.  
1. Time dependent;   
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2. Osmotic controlled; 
3. Pressure controlled;  
4. Swelling systems;  
5. Eroding systems;  
6. Those using slowed transit in the colon (pellet dosage forms) to release the majority of the drug 
when trapped in the ascending colon (Patel et al, 2012b). 
1.5.1 - pH triggered release 
In the pharmaceutical industry, pH based delivery systems constitute the majority of colon targeted 
formulations (Kumar and Mishra 2008) and, despite the new drug delivery technologies that are currently 
available, stimuli responsive polymers still stand as the most popular biomaterial used, due to their 
associated low cost of production and design/synthesis flexibility (Yoshida et al., 2013). The intraluminal 
pH is rapidly changed from highly acid in the stomach to about 6.5 in the proximal part of small intestine 
and in distal part of small intestine it is 7.5. The pH is 6.4 in caecum, 5.7 in ascending colon, 6.6 in 
transverse colon and 7.0 in descending colon (Philip and Philip, 2010).  
As we know, by changing the pH of the environment, the charge of the solute is also changed. If the pH of 
the GIT region is such that a particular biomaterial carries no net electric charge, the solute often has 
minimal solubility (Boundless – Textbooks, 2016). Therefore, these types of systems use stimuli 
responsive polymers or copolymers that show very poor solubility at highly acidic pH environments, such 
as stomach, but are soluble in the distal gastrointestinal tract, where the pH reaches values close to neutral 
(Hales et al., 2015).  
It can also be observed an extra and intracellular alteration of pH as a biologic response to disease. While 
the intracellular pH of the cells within the healthy tissues and tumours is similar, tumours exhibit a lower 
extracellular pH than normal tissues, due to the build-up of metabolites such as lactic acid and carbonic 
acid in the extracellular space. As healthy non-cancerous cells excrete metabolites from the cellular 
cytoplasm to the interstitial space, surrounding vasculature and lymphatic ducts will eliminate the 
metabolites from the tissue. In cancerous tissues, insufficient vasculature and lymphatic processes hinder 
metabolite elimination, leading to their accumulation and resulting in acidic microenvironments (Préat el 
al, 2010).  Here, the biomaterial choice plays an important role and makes it possible to engineer 
nanocarriers that can exploit these pH differences and allow for delivery of the encapsulated active 
ingredient to specifically selected extracellular or intracellular sites.  
pH sensitive polymers can be classified according to their source, as natural or synthetic, and, according to 
their nature, as anionic and cationic, depending on their charge status at pH 7.4.  To be considered as 
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suitable candidates to be used in drug delivery, they have to be biocompatible/biodegradable and have no 
toxic or immunogenic by-products.  
1.5.1.1 - Chitosan 
 
Figure 1.5 - Schematics of chemical reaction of deacetylation of chitin. Retrieved From: Elson Santiago de Alvarenga (2011). 
Among natural polymers chitosan in one of the most widely used in colon delivery due to its pH swelling 
properties. Structurally, chitosan is a straight-chain copolymer composed of D-glucosamine and N-acetyl-
D-glucosamine being obtained by the partial deacetylation of chitin, as seen of Figure 1.5 (Alvarenga, 
2011).  
Chitosan is usually combined with other polymers, by crosslinking, in order to produce stable matrixes 
and to enhance its solubility in organic fluids (Pujana el al , 2013). These matrixes are known as 
hydrogels, and they are crosslinked macromolecular networks that swell in water or biological fluids. 
They have become a potential candidate for carriers of bioactive macromolecules, wound dressing and 
controlled release of drugs (Kawaguchi, 2000). Chitosan nanogels have been widely used as bioactive 
compound delivery system that offer less toxicity, is biodegradable and biocompatible, all of that 
associated with cost efficiency (Nagpal et al, 2010).  Blends of chitosan with other polymers have been 
used as in some cases, by synergistic effects; the blend provides better properties than the pure 
components. Chitosan, due to its many functional groups, can be easily modified, and some properties, 
such as swelling behavior, can be tunable by changing the ratio between chitosan and other polymers in 
the same formulation (Islam et al., 2012). Table 1.3 presents some examples of formulations using 
chitosan blended with other polymers as pH triggered delivery system. 
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Table 1.3 - Review of some articles that use chitosan based polymer blends as a pH triggered delivery system. 




The effects of pH, 
ionic strength, and 
inorganic salt on the 
swelling behavior of 
the hydrogel were 
studied 
Hydrogel has excellent pH 
sensitivity in the range of pH 
1.40 to 4.50, pH reversible 
response between pH 1.80 and 
6.80 
Chen, S. et al. (2008) Synthesis and 
swelling properties of pH-sensitive 
hydrogels based on chitosan and 
poly(methacrylic acid) semi-
interpenetrating polymer network. 
Journal of Applied Polymer Science, v. 
98, n. 4, p. 1720-1726. 
Chitosan-alginate 




chitosan mixed beads 
and alginate-chitosan 
coated beads at 
different pH solutions 
(1.5, 2.5, 5.0, 6.8, 7.4, 
and 8.0) 
Dependent on the presence of 
the polyelectrolyte complex 
between chitosan and alginate; 
mixed beads and coated beads 
showed low release at 1.5 pH , 
and approximately 99% of 
release at pH 6.8 
Dai, Y. et al. (2008), Swelling 
characteristics and drug delivery 
properties of nifedipine-loaded pH 
sensitive alginate–chitosan hydrogel 
beads. Journal of Biomedical Materials 
Research Part B: Applied Biomaterials, 




swelling and ascorbic 
acid delivery kinetics 
at various chitosan 
concentrations, at 
acidic, neutral and 
basic pH. 
The results of the swelling study 
showed that the swelling 
properties of the network varied 
with the changes of the pH in the 
swelling solution, as well as 
concentration of chitosan. 
Martinez-Ruvalcaba (2008), A. 
Swelling characterization and drug 
delivery kinetics of polyacrylamide-co-
itaconic acid/chitosan hydrogels. 
expresspolymlett, v. 3, n. 1, p. 25-32. 
Chitosan and acrylic 
acid 
Their swelling 
behavior in different 
pH buffer solutions 
The obtained results show that 
these hydrogels have good pH 
sensitivity which can avoid drug 
release in stomach, and their 
swelling kinetics in stimulant 
intestinal environment follow 
second-order swelling kinetics 
equation. 
Gong, S. et al. (2010) Chitosan-g-PAA 
hydrogels for colon-specific drug 
delivery: Preparation, swelling behavior 
and in vitro degradability. J. Wuhan 
Univ. Technol.-Mat. Sci. Edit., v. 25, n. 
2, p. 248-251. 
Carboxymethyl 
chitosan 
pH specific delivery 
of nateglinide. pH 
responsive swelling 
behavior of prepared 
hydrogels was 
checked using 
different pH values 
(1.2, 6.8 and 7.4) 
Low swelling at pH 1.2 (for first 
2 h) and quick swelling at pH 
6.8 (for next 3 h) followed by 
linear swelling at pH 7.4 (for 
next 7 h) with slight increase. In 
vitro release profile of hydrogels 
showed biphasic release pattern 
dependent on swelling behavior 
S. Vaghani, S. et al. (2012) Synthesis 
and Characterization of Carboxymethyl 
Chitosan Hydrogel: Application as pH-
Sensitive Delivery for Nateglinide. 






1.5.1.2 - Pectin  
Pectin based delivery systems have been also one of the methods of choice regarding pH triggered colon 
delivery. Pectins are linear polyanionic polymers derived from plant cell walls, that are composed of α-1,4 
D-galacturonic acid and 1,2 D-rhamnose with D-galactose and D-arabinose side chains having average 
molecular weights between 50000 to 150000 (Chourasia and Jain, 2004a). The most notable feature of 
pectins is their gelling activity. Crosslinked polymers of pectin, can form hydrogels that are able to absorb 
and retain hundreds of times their weight of water and are known as superabsorbents (Rubinstein et al, 
1990). Also, pectin is resistant to proteases and amylase which are active in the upper GIT (Sinha and 
Kumria, 2007a). 
 
Figure 1.6- Chemical structure of pectin. Retrieved from: Pectin. (2012). 
 
Regarding chemical structure and molecular weight, they can be grouped as low methoxy (LM), high 
methoxy (HM) and amidated pectins. They have a number of pharmaceutical applications and are 
presently considered as promising biodegradable carriers for colon-specific drug delivery for systemic 
action or topical treatment of diseases such as ulcerative colitis, Crohn’s disease, and colon carcinomas 
(Sriamornsak et al, 2007). Various techniques have been reported to manufacture the pectin-based drug 
delivery systems, especially ionotropic gelation and gel coating (Birch and Schiffman, 2014). The type and 
concentration of pectin, the modifications of hydroxyl group, the pH of pectin solution, the temperature 
and the presence of cations, are some of the factors of which gel´s principal characteristics depends (Liu et 







Table 1.4 - Review of some articles that use pectin based polymer blends as a pH triggered delivery system. 
Polymer blend Experimental work Main results Bibliografy 
pectin/chitosan 
Hydrogels were 
prepared at different 






Water uptake was increased by 
raising the environmental pH 
(from 2.0 to 7.4) and the 
pectin/chitosan weight ratio, 
while drug availability was 
increased by raising the 
environmental pH (from 2.0 to 
7.4) and decreased by raising the 
pectin/chitosan weight ratio. 
Bigucci, F. et al. (2009) Pectin-based 
microspheres for colon-specific delivery 
of vancomycin. j pharm pharmacol, v. 




swelling behavior of a 
superabsorbent 
hydrogel 
The hydrogel exhibited a pH-
responsive swelling-deswelling 
behavior at pH’s 2 and 8. This 
on-off switching behavior 
provides the hydrogel with the 
potential to control delivery of 
bioactive agents. 
Sadeghi, M. (2011) Pectin-Based 
Biodegradable Hydrogels with Potential 
Biomedical Applications as Drug 
Delivery Systems. Journal of 
Biomaterials and Nanobiotechnology, v. 








between pH sensitive 
polymer coated 
tablets and natural 
polymer coated 
tablets in a various 
simulated fluids (pH 
values 1.2, 6, 6.8, 7.2, 
5). 
The lowered pH condition in 
diseased state could not trigger 
the drug release, as it was not the 
threshold pH of the particular 
coated polymer. 
Newton, A. et al. (2012) K. Pectin-
HPMC E15LV Vs pH sensitive polymer 
coating films for delayed drug delivery 
to colon: a comparison of two 
dissolution models to assess colonic 
targeting performance in-vitro. 
International Journal of Applied 
Research in Natural Products, v. 5, n. 3. 
lysozyme-pectin 
Nanocarrier for the 
antitumour agent, 
methotrexate (MTX). 
Nanogels were pH-dependent, 
accelerated release of MTX at a 
decreasing pH from 7.4 to 5.3. 
The MTT assay indicated that 
encapsulated MTX exhibited 
higher anticancer activity than 
free MTX 
Lin, L. et al. (2015) Construction of pH-
sensitive lysozyme/pectin nanogel for 
tumour methotrexate delivery. Colloids 
and Surfaces B: Biointerfaces, v. 126, p. 
459-466. 
Pectin and Eudragit 
RS30D, Eudragit 
NE30D or Surelease 
The dissolution 
profiles of pectin 
coated pellets were 
investigated in pH of 
1.2 (2 h), pH of 7.4 (4 
h) and pH of 6.8 in 
the absence as well as 
presence of rat cecal 
contents (18 h). 
Coated pellets, prepared out of 
pectin and Surelease at a ratio of 
1:3 at coating level of 35% 
(w/w), could increase 
budesonide release statistically 
in presence of rat cecal content, 
while they released no drug in 
pH of 1.2 and 7.4 . 
Varshosaz, J. Et al. (2016)N. Pectin 
Film Coated Pellets for Colon-targeted 
Delivery of Budesonide: In-vitro/In-
vivo Evaluation in Induced Ulcerative 
Colitis in Rat. Iranian Journal of 





1.5.2 - Microflora triggered release 
Although, pH based delivery approach is very common, no reliable and sufficient pH gradient exists 
between the small and large intestine, since the pH in the small intestine and in the colon are not very 
different. This could cause an unpredictable and unstandardized site-specificity and release pattern, as 
dissolution behavior of the polymers used as excipients are, normally, not sensitive to small pH 
differences (Chourasia and Jain, 2004b). The nature of the bacterial population within the GIT seems to 
be strictly linked to the variety of pHs along this channel. The upper GI tract is sparsely populated with 
acid-resistant species, such as aerobic lactobacilli and streptococci. They are mainly Gram-positive, 
facultative aerobic microorganisms.  
 
Figure 1.7- Bacterial density estimative along GIT. Retrieved from: Patel et al., 2012. 





 bacteria per gram of colonic content (Figure 1.7), which contributes to 60% of fecal mass 
(Patel et al., 2012c) The colon is the site of the most abundant microflora in the GI tract. It consists 
predominantly of anaerobic or facultative anaerobic bacteria, such as Bacteroides, Bifidobacteria, 
Lactobacillus, and Enterococci (Scheline, 1973). These microbes are so active that Bocci declared that 
colonic microflora metabolic activity is equal to the one of a virtual organ, calling it a “organ within an 
organ” or “the neglected organ”, stating that the intestinal microbiome has a metabolic activity that is both 
adaptable and renewable (Bocci, 1992), and O'Hara et al (2006) referred to it as the “forgotten organ” 
(O'hara and Shanahan, 2006).  
The colonic bacterial flora fulfil their energy requirement for the cellular function by fermentation of 
various substrates that are left indigested in the small intestine (Rubinstein, 1990).  
These substrates include di, tri and polysaccharides. To do so, these bacteria produce a wide range of 
enzymes, such as β-glucuronidase, β-xylosidase, α-arabinosidase, β-galactosidase, nitroreductase, 
azoreductase, deaminase, urea hydroxylase etc. (Kinget, 1998). Polysaccharides are polymeric 
carbohydrate molecules composed of long chains of monosaccharide units bound together by glycosidic 
linkages and on hydrolysis give the constituent monosaccharides or oligosaccharides (Chourasia and Jain, 
2004c). Besides the capacity of polysaccharides to act as substrates for the bacterial inhabitants of the 
colon, their properties, such as swelling, film forming and their biocompatability, biodegradability 
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supports their use as colon specific delivery agents (Sinha and Kumria, 2007b).  The release of the 
entrapped bioactive agent is triggered by hydrolyzation of glycosidic linkages, and, consequentely, 
depolymerization of those polysaccharides on arrival in the colon region. The main bacterial genera 
responsible for this biodegradation are lactobacilli, bacteroides and bifidobacterium (Patel et al., 2012d). 
Polysaccharides have been applied as controlled release coatings, matrices, macromolecular carriers, and 
biodegradable carriers, as they retain their integrity and prevent the release of drug during its passage 
through the GIT (Kosaraju, 2005).Furthermore, they can be chemically modified with relative ease, are 
very stable, safe, nontoxic, hydrophilic and gel forming. These microflora activated delivery systems can 
be based on drug-saccharide conjugates, or biopolymeric matrixes or coating.  
Because they are natural polysaccharides, chitosan and pectin have been evaluated for their potential as 
colon specific drug delivery in several forms such as capsules, matrices, hydrogels and microspheres. 
Chitosan, an aminopolysaccharide of animal origin, has shown to suffer enzymatic hydrolytic cleavage of 
the β-(1-4) saccharide linkage (Hirano, 1989). The increased water solubility of chitosan and its amine 
functionality has encouraged its use as a biomaterial polymer conjugate. Due to his high solubility at 
acidic pH values, it usually requires an adequate coating, which would protect it against the acidity of the 
stomach. As the formulation reaches the intestine, the pH increases and the enteric layer, which is 
normally soluble at neutral to alkaline pH, dissolves releasing the chitosan coated core. This core is 
rapidly degraded by enzymatic activity, and the payload is released. (Tominaga et al. 2001; Li, 1992; 
Tozaki et al, 1996). Chitosan formulations have been increasingly applied in CSDS synthesis due to its 
many advantageous properties: pH swelling capacity, solubility, cationic charge, colonic microflora 
degradation, mucoadhesiveness (Sogias et al, 2008), bactericide and fungicide capacity, and, additionally, 
chitosan itself has some anticancer properties (Gibot et al, 2015). 
Unlike chitosan, pectins are non-starch, linear polysaccharides extracted from plant cell walls, which 
remain intact in the stomach and small intestine, but are degraded by the bacterial inhabitants of the 
human colon. Pectin is completely fermented by microflora, low esterified pectin being fermented faster 
than high esterified pectin. In spite of that, according to Saito and colleagues, a small part of pectin can be 
degraded at acidic stomach environment via side chain hydrolysis, and at pH 5 to 6 (conditions of small 
intestine) via β-elimination of main chain or de-esterification. (Saito et al, 2005) That is why it is usually 
required to coat pectin based delivery systems, in order to protect the drug (Ashford et al, 1993; Amol et 
al, 2007). 
1.6 - PLANT DERIVED BIOACTIVE PRODUCTS  
The use and manipulation of plants and its derivatives for therapeutic and/or prophylactic purposes, is 
something that has been following the evolution of human race itself, practically since the first man on 
earth (Petrovska, 2012). It is proven by undeniable historical evidences ranging from archaeological 
 
17 
findings in the Neanderthals tombs of over 60.000 years, to several 4000 years old Sumerian clay tablets, 
which have the name of various plants and herbal extracts and its correspondent use for each disease 
(Kong JM et al, 2003). This proves that the search of cure through plants is a very ancient practice and it 
can be found in practically all cultures and societies. However, there are some problems associated with 
the direct use of unprocessed plants or herbal extracts for therapeutic ends. Those issues can include 
dosage related toxicity, or toxicity related with interactions between two or more active principles, due to 
the fact that a pure vegetal extract often has more than one active principle, their stability and 
bioavailability after administration (Wang et al, 2012a), and also, as many industrialized drugs, the low 
specificity delivery problem. All of this, associated with each individual metabolism and genetic 
particularities, results in drastic data variation. 
As time goes by, knowledge about medicine, biology, biochemistry and health technologies, have allowed 
the isolation of active principles from herbal extracts and, through study of the excipients and proper 
administration techniques that should be applied for each case, it was possible to overcome a big part of 
the existing problems. 
However, the use of plant sources applied to the improvement of health conditions was never left behind, 
and new branches of science such as nutraceuticals, ethnobotany and ethnopharmacology, are areas that 
try to bring together the most recent discoveries of science and, sometimes, millennial knowledge, about 
the healing powers attributed to the plants, present in various cultures. 
A number of active ingredients, and even unrefined natural extracts, have shown to have cytotoxic and/or 
antiproliferative effects on a range of cancer cells, in vitro, in vivo and ex vivo. Despite there is still a great 
deal of research to be done concerning the use of extracts in clinics and pharmaceutical industry, it is safe 
to say that at the present time there is in place a set of information and conditions in the areas of 
biotechnology, molecular biology, botany, pharmacognosy, and other sciences, that make up a broad 
spectrum of knowledge in this field. Among those herbal medicines, there has been a range of clinical 
studies testing the effect of some of those as anticancer agents, and some of them have proven to have 
shown at least some kind of antiproliferative or cytotoxic activity. These include curcumin from tumeric, 
genistein from soybean, tea polyphenols from green tea, resveratrol from grapes, sulforaphane from 
broccoli, isothiocyanates from cruciferous vegetables, silymarin from milk thistle, diallyl sulfide from 
garlic, lycopene from tomato, rosmarinic acid from rosemary, apigenin from parsley, and gingerol from 
gingers, Diindolylmethane/Indole-3-carbinol from brassica vegetables, cyanidins from grapes, crocetin 
from saffron, among others (Wang et al., 2012b). Each one of these bioactives has a specific mechanism 
of action, which are responsible for preventing or delaying the progression of the colon cancer. Increase 
detoxification by inhibition of cyclooxygenases, DNA methylation, modification of PI3 kinase pathway, 
and tumour angiogenesis inhibition, modification of microbial population, and regulation of inflammation, 
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etc., are some of most common mechanisms (Williams et al., 2015a). Below, some examples of plant 
derived  products, that have proven to have great potential as chemopreventive, antiproliferative and/or 
cytotoxic agents, are considered: 
 Curcumin - Curcumin (diferuloylmethane) is the major pigment of a popular Indian spice 
turmeric, Curcuma longa L., a member of the ginger family, which possesses both anti-
inflammatory and antioxidant properties (Agrawal et al., 2014; Surh, 2002).There are several 
studies that demonstrate curcumin´s anticancer activity, with many of them including studies 
referring specifically CRC cell lines. The great key factor is that it has the ability to induce 
apoptosis in cancer cells without cytotoxic effects on healthy cells, which is very attractive to 
cancer research scientists (Williams et al., 2015b). One of the mechanisms by which cancer cell 
death was observed, was through curcumin's ability to reduce pro-caspase-3 levels, polymerase-1 
cleavage and chromatin condensation, in a time- and dosage-dependent manner (Watson et al, 
2010), but many other apoptosis inducing pathways have been suggested and proved (Bachmeier 
et al, 2007; Aggarwal and Shishodia, 2004; Beevers et al, 2009). 
 Phenetyl Isothiocyanate - Phenethyl isothiocyanate (PEITC), one of the major compounds from 
dietary cruciferous vegetables, has been found to have antitumour properties and therefore could 
generate special interest for the development of chemopreventive and/or chemotherapeutic. 
(Phenethyl isothiocyanate. n.d). It is a breakdown product of the gluconasturtiin, and it is belived 
to reduce carcinogen activation by P450 enzymes (Plate, 2006). Although the mechanism of 
action is unclear, phenethyl Isothiocyanate (PEITC) was shown to induce apoptosis in tumour 
cells, possibly mediated through its metabolic intermediates, reactive oxygen species (ROS). 
PEITC also is able to have an inhibitory effect on the some important factors such as SOS-1, 
PKC, ERK1/2 and Rho A. PEITC also affected Ras, FAK, PI3K or inhibited GRB2, NF-κB, 
iNOS and COX-2 for causing the inhibition of cell proliferation in CRC cell lines (Lai et al., 
2010). 
 Momordica Charantia (bitter melon) - Momordica charantia L. Is an endemic plant in many 
country of Asia, South America and Africa, commonly known as bitter melon , and has been 
present in the traditional medicine of these countries since long ago, being used in a wide range of 
therapeutic applications, from curing infections and wound healing, to the treatment of diabetes 
and cancerous conditions (Fang et al, 2012a). All the parts of the plant are used, from the leafs to 
the root. Although some components of this plant have been identified as potential cancerous 
agents, the proteins Alpha-mormocharin (α-MMC) and Mormodica Anti-HIV (MAP30) have 
been the most studied and have shown to have anti-proliferative effect in vivo and in vitro in 
several types of cancer, including those deemed most difficult to treat. These proteins were tested 
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against pulmonary, colon, pancreatic, liver, epidermal, breast and melanoma cancer (Fang et al, 
2012b; Meng et a., 2014). α-MMC e MAP30 are categorized as type 1 Ribosome Inactivating 
Proteins (RIP). They are constituted by a polypeptide chain of approximately 30 Kda, that exert 
their toxic effect by a linkage to the major subunit of ribosomal 60s. They act as a N-glicosidase, 
cleaving specifically A4324 adenin in rRNA 28S ribosomal subunit, as a result, factor 2, which is 























2. AIMS AND OBJECTIVES 
This work was developed as part of a large ongoing project - iNOVA4Health-Advancing Precision 
Medicine - that involves several research institutions, including IBET and ITQB and Portuguese Institute 
of Oncology (IPO). 
This dissertation has, as primary goal, the engineering of smart carriers, through which it would be 
possible to evaluate and improve the cellular uptake of bioactive agents: This carriers would be able to 
deliver bioactive agents directly and specifically to CRC cell, by responding to certain external stimuli as 
pH and charge, and by degradation of the carrier by glycolytic enzymes produced by colonic microflora. 
They could be used as an adjuvant or neoadjuvant orally administrated cancer therapy.  
The strategy used is the synthesis and characterization of different microcarriers based in chitosan and 
citrus pectin, both multilayer and complexed polymers, in order to define the best synthesis method and 
formulation, as well as determining the best encapsulation method. 
 One of the particles is multilayered, constituted by chitosan and citrus pectin. Chitosan, for its 
properties, like muchoadherence, as colon is a mucosa. This propriety helps particle to cling to the 
colon walls, resisting better to the peristaltic movement. Chitosan positive charge is also strategic, 
as it will electrostatically attract the particle to the cancer cell agglomerate, as cancer cells are 
negatively charged, and its swelling at acidic pH will help particle degradation when it arrives to 
the caecum and ascending colon. The particle will start to be degraded by bacterial enzymes as 
soon as it achieves colon region. Citrus pectin in the particle will be recognized by Galectin-3 
receptors. All of this will make the payload release to occur just in cancer site. 
 The other particle is a PEC complex, blending chitosan and citrus pectin. In this system, what is 
being valued, is the mucoadherent properties and the enzymatic lyses that occurs in both 
biomaterials. In this case, chitosan quantity is higher than citrus pectin quantity, in the particle 
structure, rendering the overall charge of the particle positive, therefore, making the particle 
electrostatically attracted to CRC cells. Citrus pectin, which is also present at the particle surface, 
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3. EXPERIMENTAL SECTION 
3.1 - MATERIALS AND REAGENTS 
 Chitosan - low molecular weight chitosan, with a molecular weight of 190-310 kDa, and 75-85% 
deacetylated, from Sigma-Aldrich; CAS Number 9012-76-4. All chitosan solutions were prepared 
in acetic acid solution (5%). 
 Pectin from citrus peel - Modified citrus pectin (MCP), with ≥74.0% of galacturonic acid at dry 
basis and ≤10% of impurity (moisture); CAS Number 9000-69-5 All MCP solutions were 
prepared with MilliQ® water. 
 Calcium chloride (CaCl2) - from Kemira, imported and packed by José M. Vaz Pereira, Lda., 
80+0,5% of purity; CAS number 10043-52-7. All CaCl2 solutions were prepared with MilliQ® 
water. 
 Acetic acid - CH3CO2H –96% from Sigma-Aldrich; CAS Number 64-19-7. 
 Cyclohexane - C6H12 –99+% from Alfa Aesar; CAS number 110-82-7. 
 1-hexanol - C6H14O –99% from from Alfa Aesar; CAS number 111-27-3. 
 Acetone (CH3COCH3) –  ≥ 99,5%  from Sigma Aldrich, CAS number 67-64-1. 
 Phenethyl isothiocyanate (PEITC) –99% from Sigma Aldrich; CAS number 2257-09-2 
 5-Fluorouracil - 5-FU (C4H3FN2O2) –99% from  from Sigma Aldrich; CAS number 51-21-8 
 MilliQ® apparatus - Mini Spray Dryer B-290 
 Ibuprofen Sodium - ≥ 98%  from Sigma Aldrich, CAS number 1568-27-1 
 
Instrumental 
 Spray Drying apparatus – Mini Spray Dryer B-290 from Buchi 
 Impregnation apparatus -   artisanal apparatus for the supercritical impregnation was adapted from 
(Varona, Rodríguez-Rojo, Martín, Cocero, & Duarte, 2011) and is schematically represented in 
Figure 10. 
 Spectrophotometer – ThermoSpectronic, Genesys 10uv 
 Scanning Electronic Microscopy apparatus (SEM) – FEG-SEM da marca JEOL, modelo 
JSM7001 (Japan) 
 Dynamic Light Scattering apparatus (DLS) -  Zetasizer Nano Series, Malvern Instruments Ltd, 
UK 
 Centrifuge 1 - Avanti J-26XP Beckman Coulter 
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3.2 - SYNTHESIS OF CHITOSAN AND CITRUS PECTIN PARTICLES BY SPRAY 
DRYING METHOD 
3.2.1 – Introduction 
The aim of this synthesis was to build through bottom up approach, a microparticle resulting from a 
chitosan and citrus pectin polyelectrolyte complexation (Figure 3.2), by spray drying. The basic steps in 
the microencapsulation through this method, involves the preparation of a stable and homogenized 
solution to be processed and subsequently atomized, and the dehydration of the resulting particles. In the 
case here presented, chitosan being in higher amount will confer an overall positive charge to the particle, 
contributing that to the electrostatic attraction between particle and CRC cells.  The particle will start to be 
degraded by bacterial enzymes as soon as it achieves colon region. Citrus pectin in the particle will be 
recognized by Galectin-3 receptors. All of this will make the payload release to be just in cancer site, 
minimizing, thus, the uptake of the bioactive agent by healthy cells. This method is considered “green”, as 
it does not requires the use of organic solvents. 
3.2.2 - Experimental procedure 
The synthesis of chitosan:citrus pectin (CS:CPect) polielectrocomplex (PEC) was performed according to 
procedure previously published (Grabnar and Kristl, 2010), with some modifications. CS:CPect polymer 
blend (CS:CPect ratio = 2:1) was prepared in a two-step procedure based on the ionotropic pre-gelation of 
the pectin solution (2.13 mg/mL), with CaCl2 (0.806 mg/mL) (CaCl2:CPect ratio = 1:10), in order to lead 
the formation of macromolecular aggregates shown at Figure 3.1 (“egg-box” cavity).  
 
Figure 3.1 - Pectin has the ability to cross-link with divalent ions such as calcium ions. Pectin, being hydrophilic, forms a gel 
upon swelling. When calcium chloride concentration increases, the pectin’s ability to swell is reduced (Maestrelli et al., 2008). 
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CaCl2 solution (10 mL) was injected under gentle stirring into a beaker containing 40 mL of pectin 
solution (2.625mg/mL) and stirred for 10 min to provide a pre-gel. Afterwards, that pre-gel, was slowly 
injected through a capillary micropipette into the 220 mL chitosan solution (0.938 mg/mL), under 
vigorous stirring, and the resulting solution was left under stirring for 24 hours. For loading studies, 20 
mL of Ibuprofen solution and Phenetyl Isothiocyanate (PEITC), by using 20 mL of Ibruprofen solution in 
acetone (3 mg/mL) and by adding that solution to the pectin solution before the addition of CaCl2. This 
solution was passed through Mini Spray Dryer, setting the maximum inlet temperature to 150 ºC, the 






3.2.3 - Particle characterization  
Chitosan and citrus pectin PEC particles were subjected to DSC study, to determine the size and to 
evaluate the pH responsiveness, through suspending about 0.5 mg of dry particles in 1.5 mL of MilliQ 
water that was treated with 1M NaOH or 1M CH3CO2H, in order to regulate pH to 3.66 , 5.2 , 7.1 , 8.2 , 
10.22. SEM imaging was also performed as a means of measuring dry particle diameter, and to analyze 
particle morphology. 
3.2.4 - Yield 
Dried microparticles were accurately weighed, and considering the total amount of drug and polymers 
used for preparing the feed solution, the yield of production (YP) was calculated, as a percentage, using 
the following equation: 
𝑌𝑃 =
𝑀𝐶
𝐶𝑆 + 𝐶𝑃𝑒𝑐 + 𝐼𝐵
 𝑥 100 
where MC stands for the amount of produced microspheres and (CS + CPec + IB) for the sum of the 
amounts of two types of polymer and ibuprofen solubilized for the preparation of microparticles.  
Citrus Pectin 
Chitosan  
Figure 3.2 - Representation of PEC resulting particle with the encapsulated bioactive agent. 
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3.2.5 - Encapsulation efficiency determination 
To determine the exact amount of ibuprofen encapsulated into CS:CPec matrix, the total amount of 
particles obtained were suspended in 20 mL etanol, so that the non-encapsulated ibuprofen could be 
solubilized. Later, that solution was centrifuged at 13.000 rpm for 20 mn, and the supernatant was 
removed, filtered, and a sample of 2 mL was withdrawn from this solution, to determine the ibuprofen 
particles content. Another ibuprofen solution was prepared at the concentration of 0.1 mg/mL and diluted 
with etanol (1:3, 1:4, 1:6, 1:10, 1:15, 1:20, 1:40) in order to prepare a calibration curve with ibuprofen 
solutions with known concentrations. All solutions were assayed spectrophotometrically at 264 nm.  
3.3 - SYNTHESIS OF CHITOSAN COATED CITRUS PECTIN PARTICLES BY 
INVERSE MICROEMULSION METHOD 
3.3.1 – Introduction 
A microemulsion is defined as a thermodynamically stable isotropic dispersion of two immiscible liquids, 
since the domain of either or both liquids has been stabilized by an interfacial film of surface-active 
molecules (Tartaj et al, 2003). The surfactant molecules limit the nucleation, growth, and agglomeration 
of the particles. In inverse microemulsion, it constitutes one barrier that separates the continuous phase 
from the disperse phase, in other words, the oil phase from the aqueous phase. (Bagwe et al, 2001). Due to 
the very small size (nanometer range) of the core, the particles formed usually have a very small size, 
sometimes less than 15 nm and a very narrow size distribution. However, the particle size can be 
controlled by controlling the size of the core and the duration of the reaction (Munshi and Maitra, 1997). 
The aim of this synthesis was to develop a multilayer particle (Figure 3.3) that would be able to achieve 
specifically CRC cells with minimum damage to normal cells. The external layer would be made of 
chitosan; this will make the particle to be electrostatically attracted to CRC cells, placing the particle near 
cancer cells region. Simultaneously, microflora enzymes will start to degrade the chitosan layer, revealing 
the inner core: citrus pectin. Citrus pectin, as in the particle synthesized above, will be recognized by 
galectin-3 receptors, making the particle to “anchor” in CRC cell´s surface. After particle degradation, the 
payload will be delivered directly at the cancer site. 
3.3.2 - Experimental procedure 
Chitosan coated particles were prepared using the IM methodology. Primarily, a 4mg/mL chitosan 
solution was prepared by dissolving it in acetic acid; once it was completely dissolved, 2 mL of hexanol 
and 10 mL of cyclohexan were added to 5 mL of chitosan solution, under stirring. Then Triton X-100 was 
added to that solution, until the solution became clear, to form the microemulsion. The second solution 
was obtained by dissolving pectin into MilliQ water (3.33 mg/mL), followed by the addition of 0,5mL of 
CaCl2 (3 mg/mL), under stirring. Then, same quantity was added the of n-hexanol and cyclohexan that was 
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added to the chitosan solution. Triton X-100 was also added drop-by-drop into this solution until it 
became translucent. After having both solutions, pectin microemulsion was added drop-by-drop to the 
chitosan microemulsion under vigorous stirring.  
This last mixture was kept under stirring for 10 days at room temperature. A sample of the solution was 
taken by the third, sixth, seventh and tenth day, washed with anhydrous ethanol, centrifuged at 13000 rpm, 
and the pellet was re-suspend in MilliQ filtered water. 
3.3.3 - Particle characterization  
Chitosan and citrus pectin PEC particles were subjected to DLS studies, in order to determine the size and 
to evaluate the pH responsiveness, through suspending about 0.5 mg of dry particles in 1.5mL of MilliQ 
water that was treated with 1M NaOH or 1M CH3CO2H, in order to regulate pH. This characterization was 






 day of reaction. SEM imaging 











3.4 - ENCAPSULATION OF PHENETYL ISOTHYOCYAONATE BY SUPERCRITICAL 
CO2 IMPREGNATION 
3.4.1 - Introduction 
The impregnation by supercritical CO2 (SCCO2) method allows incorporation of the active compound into 
previously synthesized particles of carrier material. It has been demonstrated that the supercritical 
impregnation technique allows a highly accurate and reproducible drug loading of large arrays of 
microcontainers (Marizza et al, 2014). At high pressure, CO2 can be dissolved in most polymers, resulting 
in a considerable swelling of the polymer. The increase in the free volume of CO2 swollen polymers 




improves the diffusion rate and penetration of solute molecules into the polymeric matrix. It consists in the 
deposition of a soluble substance, the PEITC, in a super-critical fluid into the polymer matrix upon 
depressurization. In this way, even a solute that has low affinity for the polymer matrix can be trapped 
within a polymer matrix (Varona et al, 2011a,  Kikic e Vecchione, 2003). As essential oils are highly 
soluble in SCCO2 (Varona et al, 2011b) its believed that once SCCO2 is released into the cell that contains 
PEITC, it will dissolve in the extract, forming a PEITC/CO2 mixture. That mixture will pass through the 
polymeric microparticles, with the SCCO2 making the particles swell, so the PEITC can, through 
diffusion, go into the carriers. To “lock” PEITC inside the particle, depressurization is required, and it can 
be done slowly or rapidly.   
This method is also considered “green” as it does not involve the use of any organic solvents. 
 
 
Figure 3.4 - Scheme of an impregnation apparatus. MS: magnetic stirrer, VV: vent valve, PT: high pressure transducer, TC: 
temperature controller. Retrieved in: Varona et al, 2011. 
3.4.2 - Experimental Procedure 
The previously prepared particles (synthesized by spray drying described at 3.2) were used in this 
procedure. In this procedure, the polymer is exposed to the solute solubilized in carbon dioxide for a 
predetermined period, followed by controlled depressurization of the system. When the system is 
depressurized, the carbon dioxide molecules leave the polymer matrix while the solute molecules remain 
trapped inside. This operation was carried out in an artisanal reactor.  Figure 3.4 depicts a schematic of 
the high pressure setup used in the impregnation experiments, according to the procedure described at 
Varona and colleagues (Varona et al, 2011c).  This discontinuous apparatus consists of a high pressure 
stainless steel impregnation cell (22 cm3 of internal volume), a high pressure CO2 liquid pump, a 
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temperature controlled bath, a magnetic stirring plate and a pressure transducer. The cell contains the 
PEITC (300µL) at the bottom and the CS:CPect particles to be impregnated (300 mg) were wrapped into a 
small piece of filter paper which was then stapled to avoid particle loss in a stainless steel mesh elevated 
from the bottom of the cell by a support. The impregnation cell was immersed in the water bath until 
heated to the defined temperature (35ºC). When the set point temperature was achieved, the on/off valve 
was gradually opened and the impregnation cell was slowly filled with CO2 at the pressure of 100bar. In 
those conditions, PEITC was mixed with SCCO2 while homogenization was achieved by magnetic 
stirring. The impregnation time was 24h. At the end of the experiments the SCCO2 was released through 
an on/off purge valve. Two different depressurization methods were tested: rapid depressurization (RD) – 
with total depressurization time: approximately 2 min (depressurization ~ 50bar/min) - and slow 
depressurization (SD) – with depressurization rate of 2–2.5 bar/min.  
3.4.3 – Characterization 
 Derivatization and quantification of loading capacity 
The amount of essential oil impregnated in CS:CPect particles was determined by derivatization, using the 
1,2-benzenedithiole-based cyclocondensation assay,  followed by chromatographic analysis. 100 mg of 
impregnated particles were dissolved in 30 mL of acetic acid, under stirring during 10 minutes. The entire 
derivatization procedure was developed according to the protocol described at Anex 1, with small 
changes, namely, by adapting the stock solution preparation that was described in the original protocol, 
which was settled for phenyl isothiocyanate (PITC) instead of PEITC, making the necessary changes. The 
sample utilized was prepared by dissolving 100 mg of impregnated particles in 30 mL of acetic acid, 
keeping the particles under stirring in that solution for 10 minutes, followed by a 20 minutes 6000 rpm 
centrifugation. 
Both the calibration curve and the samples were prepared according to the protocol, and the absorbance 
was later read. The samples used in RD and SD were added, each one to one previously prepared solution 
of 900 µL of 100 mM of phosphate buffer and 900 µL of methanol, and, subsequently, 100 µL de 80 mM 
1,2-Benzeneditiol were added to initiate the reaction. To make the calibration curve, 6 samples were 
prepared, including a blank, to PEITC concentrations of 512, 256, 128, 64, 32 and 0 µM. The samples 
were diluted as follows: 1:1, 1:50, 1:100, 1:200. The derivatization reaction was allowed to occur for 2h 
hours at the temperature of 65ºC. Finally, the supernatant was removed and used to quantify the PEITC 





4. MAIN RESULTS AND DISCUSSION 
4.1 – SYNTHESIS OF CHITOSAN AND CITRUS PECTIN PARTICLES BY SPRAY 
DRYING METHOD  
4.1.1 – Particle morphology and size 
 
 
Figure 4.1 - SEM images of CS:CPect microparticles prepared by spray drying technique at A) 2,000 x and B) 5,000 x C) 2000 x 
D) 10000 x magnification. A and B are unloaded particles, C and D are loaded with ibuprofen. 
Scanning electron microscopy was used to visualize the diameter, structural and surface morphology of 
the spray-dried particles. Figure 4.1 presents the images of the pulverized particles obtained by electronic 
microscopy. Spray-dried unloaded particles showed similar characteristics: particles had spherical shape 
and heterogeneous size, presenting a smooth surface, but with some concavities. One factor that could be 
involved in particle deformation is the inlet temperature. Wenjie Liu and colleagues found that the drying 
temperature played an important role in the morphology of spray-dried chitosan based microparticles (Liu 
et al, 2010a). There is a direct correlation between high inlet temperatures (and consequently high outlet 
temperatures) and particle deformation. Inlet temperatures from 160 to 180ºC “resulted in cap-shaped 
microparticles”. Maa and coworkers explained this phenomenon by focusing on the drying rates 






When the internal vapor pressure surpasses the range of pressure that the crust can resist, the semidried 
droplets collapse and forms dimples (Maa el at, 1997). 
In contrast, loaded particles presented a highly irregular surface and shape, although the particle 
distribution was still positive. Ibuprofen loaded CS:CPec microspheres presented a collapsed surface, as 
shown in Figure 4.1 (C e D imagens). According to the literature, the concentration of the solution to be 
sprayed has an important role in particle´s shape and overall morphology (Liu et al., 2010a) The solutions 
prepared to obtain both unloaded and loaded particles were exactly alike, except for the addition of 
ibuprofen in the second case, making, thus, that solution more concentrated compared to the first one. This 
fact can explain the morphology of the ibuprofen loaded particles.  
Another plausible explanation is a possible interaction between the polymers and the drug. Liu and 
coworkers also showed that ibuprofen can form complexes with chitosan, by positioning close to (and in 
front of) the amino groups of the low molecular weight chitosan, involving ionic interaction between the 
ammonium groups of chitosan and the carboxylate anion of ibuprofen (Liu et al, 2011b). The CS:CPec 
PEC formation happens with the interaction between the ionized amino groups of chitosan (NH
3+
 ) and the 
ionized carboxyl acid groups (COO
–
 ) of pectin (Coimbra et al, 2011). It is believed that electrostatic 
interaction between the positively charged amino groups at C-2 of the chitosan pyranose ring and 
negatively charged carboxyl groups at C-5 of the pectin pyranose ring allow the formation of PEC, with a 
network structure, from the chitosan and pectin (Rashidova et al., 2004). With both citrus pectin and 
ibuprofen tending to form complexes with chitosan by ionic interaction with the same ionic group, it is 
possible that the simultaneous presence of these two components has led to a change in the conformation 
of the original PEC´s structure, which had an impact on the particle´s shape and morphology.  
4.1.2 - Yield 
The yields of spray-dried powders were quantified according to the previously used amount of polymer, or 
in the case of use of drug powders, the total amount of pulverized material. It is undeniable that the yield 
depends directly on the quantity of total amount of powder, in this case CS+CPec+IB (Maury et al, 2005). 
As when we can see in the equation:  
𝑌𝑃 =
371𝑚𝑔
206.4𝑚𝑔 + 105𝑚𝑔 + 60𝑚𝑔






When 371.4 mg of total powder quantity were used, the obtained powder weighted 114.9mg, thus the 
yield was 30.9%, however when that quantity is increased to 1500 mg, the yield raises to 43.6%.  
4.1.3 – Encapsulation efficiency 
According to the concentration of ibuprofen in the withdrawal sample, the encapsulation efficiency was 
very high. The obtained absorbance was compared with a series of absorbance values form solutions of 
known ibuprofen concentrations (Figure 4.2). 
 
Figure 4.2 - Graphic representation of the concentration of the diluted initial solution of ibuprofen (0.1 mg/mL) and the 
correspondent absorbance, obtained through spectrometry, for each one of the dilutions. 
Posteriorly the achieved values were used to build a calibration curve and to determine the equation of the 























Figure 4.3 - Equation of the line of the absorbance readings presented at Figure 12. 
The obtained absorbance of the sample retrieved from the particle suspension supernatant was 0,130, 
which, when correlated with the other absorbance and concentration values using the Beer-Lambert law: 
𝐴𝑏𝑠 = 𝜀. ℓ. 𝐶 + 𝒷 
,lead to a concentration of 0.207 mg/mL. 𝜀 and 𝒷 were replaced according with the data provided for the 
equation of the line, as following: 
0.130 = 2.5236.1. 𝐶 + 0.0005 
The C (concentration) found was 0.0513 mg/mL, which when multiplied for the value of dilution (40mL), 
gives us 2.052 mg of non-encapsulated ibuprofen in the final powder. 
To obtain the real encapsulation efficiency, it was necessary to adjust that result to the yield. The total 
ibuprofen amount present in the solution to be spray dried was 60mg for 371.4 mg of powder 
(chitosan+pectin+ibuprofen). The final weight of the obtained particles was 114.9 mg (after spray drying), 






y = 2.5236x + 0.0005 



























IBi being the ibuprofen present in the solution to be spray dried, IBf being the final ibuprofen quantity in 
the recollected spray dried product, and TPf and TPi being, respectively, the final and the initial total 
amount of powder. The resulting value is 18.562 mg of ibuprofen.  
Knowing that were 18.563mg of ibuprofen in the powder and from that quantity, 2.052mg were non-
encapsulated, it was possible to postulate that there was 89% of encapsulation of ibuprofen. 
This rate of encapsulation is very good and shows that there is a substantial entrapment of the drug 
between the polymeric matrixes, as stated in the literature (Rabindra et al., 2012). It states as a very good 
method of simultaneously synthetizing the particle and encapsulating the bioactive compound, having the 
advantage of being relatively easy to perform, cost effective and it dispenses the use of organic solvents. 
4.2 - SYNTHESIS OF CHITOSAN COATED CITRUS PECTIN BY PARTICLES 
INVERSE MICROEMULSION METHOD 
4.2.1 – Particle morphology and size through SEM 
 
 
Figure 4.4 - SEM images of CS:CPec particles, A and B being unloaded particles and C and D being PEITC loaded particles. 
The morphology of the CS:CPec particles obtained, as shown by the SEM images in Figure 4.4, indicates 
that the chitosan particles have a regular surface, spheroid  shape, with size ranging from 150 to 300 nm 
(image A and B) and 50 to 150 nm (image C and D), and have nearly uniform particle size distribution, 
A B




which is very important for delivery. The molecule of calcium chloride has one calcium ion (+2) and two 
chloride ions (-1), which means that the overall charge for the molecule neutral. Calcium chloride salts 
can also form crystals based on these same ionic properties. Positive calcium ions can orient themselves so 
that they are close to the negative chloride ions in another molecule (Albert, K. S., 1928). This allows for 
the formation of solid crystal structures, shown on images A and B. In PEITC loaded particles, a lower 
concentration of CaCl2 was used, and, shown on the Figure 4.4, the crystal formation is practically 
inexistent.  
It can also be observed that the reaction time affects the particle size and size distribution: loaded particles 
are smaller and less uniform than the unloaded ones, as they were stirring for only six days, and unloaded 
particles were left stirring for seven days. That translated into a moderate increase of the particle diameter. 
This fact is more explored with DLS analysis.  
Due to the electron beam of the microscope, some small CS:CPec particles fused given rise to larger ones. 
4.2.2 – DLS size measurement and pH responsiveness assays 
DLS, also known as photon correlation spectroscopy, is one of the most used methods used to determine 
the size of particles. Particle size can be determined by measuring the random changes in the intensity of 
light scattered from a suspension or solution.  This technique is commonly known as dynamic light 
scattering (DLS), but it can also be designated correlation spectroscopy (PCS) or quasi-elastic light 
scattering (QELS). DLS was used both to measure particle size and the size alteration resulting from pH 
variation, as both polymers are pH sensitive. 
Table 4.1- Particle size measurement by DLS after 3 days of reaction, in different pH solutions, and the average, median and 
standard deviation of the most intense peak. The sizes are presented in manometers. N = 4.  
  pH1.7   pH7.2   pH13.5 
Size1 Size2 Peak 
Intensity % 
Size1 Size2 Peak 
Intensity % 
Size1 Size2 Peak 
Intensity % 


















1º 1204 0 100 0 
2º 153.9 0 55 45 2º 694.5 0 100 0 2º 1308 0 100 0 
3º 400.8 0 55.1 44.9 3º 618.1 0 100 0 3º 1253 0 100 0 
4º 592.1 144.3 58.5 41.5 4º 1123 144.3 92.1 7.9 4º 1155 0 100 0 
5º 348.4 158.5 58 42 5º 1084 158.5 89.9 10.1 5º 1761 4987 74 19.8 
Average 326.5    Average 860.4    Average 1336    
Median 348.4    Median 782.5    Median 1253    
Standard 
Deviation 
188.6    Standard 
Deviation 
229.8    Standard 
Deviation 





Figure 4.5- Bar chart representing the first peak median of the particle size for each pH value. pH value affects directly the size of 
the particles. The error bar represents the standard deviation. 
With the sample collected after 3 days of stirring, were prepared three suspensions at pH 1.7, 7.2, 13.5, 
and the resultant size variation is represented on the Figure 4.5. A concentration of 0.25mg/mL was used 
for each of the preparation. As it can be observed in Table 4.1 the particle size is not very constant along 
the measurements, especially the median and standard deviation data shows that there is a large 
discrepancy between each measurement, and more than one peak appeared (% of peak intensity). So it can 
be assumed that 3 days of crosslinking reaction are not enough to obtain a uniform particle size 
distribution. The literature stated that the particles respond to pH differences by swelling at lower pH 
values and shrinking at low pH values, as the chitosan outer layer tends to swell and/or degrade in 
simulated acidic conditions. The acidic pH represents an increase of the diameter, due to intramolecular 
electrostatic repulsions. (Makhlof et al.,2011). However, that fact could was not clear with the data 
presented at Table 4.1. 
It is also interesting that the size of the particles at pH 1.7 is initially very small and, along increases with 
time. The continuous increase of the diameter as a function of time that was observed indicates 
aggregation of the system. According to the literature, chitosan based particles exhibit charge cancellation 
at neutral to alkaline pH values. The absence of repulsive electrostatic forces affects both intra and 
intermolecular interactions. This causes the system to lose its colloidal stability, causing the uncharged 
particles to start to aggregate. Since the pKa value of the chitosan is close to neutral pH, particles tend to 
spontaneously aggregate as a result of the decreased degree of protonation of chitosan in neutral to basic 




























Table 4.2 - Particle size of CS:CPec particles after 6 days of crosslinking reaction  in three different pH solutions. It can be 
observed that the peak intensity was 100% in every 















1 measurement 1 536 100 0.432 450.5 100 0.363 761.9 100 
2 measurement 1 577 100 0.372 888.6 100 0.445 763.4 100 
3 measurement 1 545 100 0.252 1058 100 0.418 1024 100 
 
 
Figure 4.6 - Bar chart representing the median of particle size at 6 days of crosslinking reaction, at different pH values, with 
standard deviation represented as error bar. N=4. 
The data referring to the particles whose reaction was stopped at the sixth day, confirms that the size of 
the particles becomes more uniformly distributed. A new parameter has been new parameter: PdI 
(polydispersity index), in order to help the better interpretation of the results. PdI is used to describe the 
degree of “non-uniformity” of a distribution. For a perfectly uniform sample, the PdI would be 0.0. 
In view of the first measurement results in Table 4.2 and Figure 4.6, it can be agreed that the particle 
diameter increased from 450.5 nm at pH 5.5 to 536 nm at pH 3.0, as it was expected. At pH 5.5 the 
particles aggregate over time, probably because of the approximation of the pKa value. However, the PdI 
values indicates that particle size is stable at pH 5.5 and at pH 7. At pH 7, as expected, aggregation of the 
particles is present, with the aggregates presenting similar sizes. The particle size shown at pH 3.3 is also 
stable, even though the PdI is the highest. That high PdI is certainly due to the partial dissolution of 
chitosan coat, what would make the particle to start to have irregular sizes. That phenomenon is described 

























solubility at acidic pH than at neutral pH” (Sako et al, 2013). So, it can be concluded that the swelling 
behavior of chitosan has a limit. When the pH value is very low (~3 and below) chitosan, instead of 
swelling, becomes soluble in water (Figure 4.7), smaller particles are observed, because the particles are 
partially or completely devoid of the chitosan coat. Even for the particles whose size was measured after 3 
days of crosslinking reaction, it can be seen that the diameter of those that were at pH 1.7 was very small 
in the first two measurements and increased with time.  
                                 
Figure 4.7 - The first image (A) represents the particle at very acidic environment. The chitosan layer swelled and started to 
dissolve. The second image (B) shows the exposed negatively charged citrus pectin core, in an acidic solution. 
Pectin pKa is approximately 3.5. Pectin hydrogels are typically spreadable, with rigidity increasing as pH 
falls below pectin pKa (Dixon, 2008). Below the pKa, less dissociation of H
+
 results in greater hydrogen 
bonding of the pectin chains, thus originating a stiffer hydrogel (Moreira et al., 2014). This may explain 
the instability of the particle size along the measurements at pH 1.7.   
To prove that the particles do lose the chitosan layer in highly acidic environment, a new DLS experiment, 
with particles being suspended in 4 different pH solutions, was performed.  
Table 4.3 - Particle size measurement by DLS after 10 days of reaction, in four different pH solutions, and the average, median 
and standard deviation. All peak intensities were 100%. The particle size is presented in nanometers. N = 4. 
  pH 3.07 PDI pH5.0 PDI pH 7,6 PDI pH 10.4 PDI 
1 run 1348 1 2136 0.432 712.4 591 615.7 0.71 
2 run 1425 1 3709 0.37 1294 1 458.7 0.27 
3 run 1949 1 3993 0.252 2860 0.467 712.4 1 
 pH 3.07 pH 5.0 pH 7.6 pH 10.4 
Average 1574 3279.3 1622.1 595.6 






The effect of pH on particle size is once again noticeable in the 10 day particle crosslinking reaction DLS 
measurements, presented on Table 4.3.  Taking as reference the first measurement of the particle size at 
pH 7, it can be seen that the particle size decreases at higher pH (10.4) from 712.4 nm to 615.7 nm, due to 
the shrinkage of the chitosan layer, and increases at lower pH (5.0) from 712.4 nm to 2136 nm, due to the 
swelling of the chitosan layer. The effect of really low pH (3.07) in particle size was also very clear: there 
is a shift in size comparing to the size verified at pH 5.0. The size changes from 2136 nm (pH 5.0) to 1348 
nm (pH 3.07), which is clearly due to the dissolution of part of the chitosan layer. The PdI value also 
confirms the instability in size and shape at pH 3.07. 
In order to explore the stability of the particle size and the reversibility of the chitosan layer dissolution in 
highly acidic environment, the particles were kept in the respective solutions for 24h and their size was 
analyzed again through DLS. The results are shown in Table 4.4. The PdI in every measurement is 1, so 
the stability of the particle size is lost, for being that long in solution. Yet, by looking upon the size of the 
particles in each pH solution, the results are as expected and in accordance with the ones achieved in the 
first measurements (Table 4.3). The particles in pH 3.07 are much smaller, so it can be assumed  
Table 4.4 - Particle size measurement by DLS after 10 days of reaction, presented on Table 6, after being 24h in suspension in the 
respective pH solutions. The only exception goes to the particles at pH 10.4. To the solution that had pH 3 was added NaOH in 
order rapidly raise the pH to 14. The particle size is presented in nanometers. N = 4. 
  PDI pH 3 PDI pH 7.6 PDI pH 11 PDI pH 14 
1 run  1 548.2 1 825 1 1314 1 120.1 
2 run  1 712.4 1 1859 1 1134 1 53.45 
3 run  1 255 1 2292 1 958.6 1 4.253 
  pH 3 pH 7.6 pH 11 pH 10.4 
Average  505.2 1658.667 1135.533333 59.2677 
Standard 
Deviation 
231.7119764 753.739 177.7049615 58.142 
 
that the chitosan layer eventually dissolved completely or almost, leaving just the citrus pectin core. In 
order to investigate the reversibility of the chitosan layer dissolution, the pH 3.07 solution was basified to 
the pH value of 10.4, by adding NaOH. In this way, the particles present in the highly acidic pH solution, 
suffered a drastic change in the environmental pH, as it was abruptly changed to a very alkaline value. The 
results presented in the Table 4.4 show  that the chitosan layer not only does not reconstitute itself around 
the citrus pectin core, but also that the particle size diminishes drastically to very low diameters, leading 
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the particle to nearly disappear. This phenomenon is due to the fact that “anionic polymers with carboxyl 
groups have higher water solubility at basic pH than at acidic pH” as reported by Sako and colleagues in 
2013. That is to say that the pectin core - which will incorporate the payload - also becomes soluble.  
4.3 - ENCAPSULATION OF PEITC BY SUPERCRITICAL CO2 IMPREGNATION 
4.3.1 – Derivatization and quantification of loading capacity 
According to the values presented above, the results point to an encapsulation capacity lower than 1% for 
both SD and RD. Due to the very negligible values obtained, only the undiluted sample was used for 
calculation. After replacing the values at the equation of the line (Figure 4.8), the PEITC concentration 
obtained in SD was 0.02187 g/L (Table 4.5). When that value is divided by the PEITC in the acetic acid 
solution (3.3 g/L), the encapsulation % is 0.66. That means that for each 99,34g of polymer, there is 0.66 g 
of PEITC. When it comes to RD, the concentration obtained was 0.00838 g/L (Table 4.6). 
Table 4.5 - Presentation of the concentration and absorbance results, in duplicate, regarding the slow depressurization (SD) for 
each sample´s dilution.  The average, standard deviation and variation coefficient were calculated for each sample. The results 














 Concentration(µM) Average 
(µM) 
SD (µM) CV 
(%) 
1/1 0.29 0.28 137.05 130.86 133.95 4.38 3 
1/50 -0.05 -0.04 -23.43 -1076.19 -549.81 744.41 -135 
1/100 0.011 0.06 4.19 2514.29 1259.24 1774.91 141 
1/200 0.02 0.03 9.90 2457.14 1233.52 1730.46 140 


















Table 4.6 - Presentation of the concentration and absorbance results, in duplicate, regarding the rapid depressurization (RD) for 
each sample´s dilution.  The average, standard deviation and variation coefficient were calculated for each sample. The results 


















1*1 0.12 0.11 53.71 48.95 51.33 3.37 7 
1*50 -0.03 -0.03 -861.91 -861.91 -861.91 0.00 0 
1*100 -0.02 -0.03 -1247.62 -1676.19 -1461.96 303.05 -21 
1*200 -0.01 -0.03 -1352.38 -3066.67 -2209.52 1212.18 -55 














Figure 4.8 - Calibration curve and the respective equation of the line used to determine the PEITC concentration for SD and RD. 
From the results obtained, it is clear that the impregnation method has a very poor efficiency in PEITC 
encapsulation into CS:CPec particles. One of the possibilities that could justify these unpromising results 
is the chosen method of PEITC release. While in spray drying encapsulation, the loading capacity was 
calculated through the calculus of the % of non-encapsulated active principle; in the impregnation it was 
necessary to calculate the % of the encapsulated active. So, it was necessary to add one step in which the 
release of the payload happened. To release the payload, the particles were destroyed by placing them into 
a 10% acetic acid solution, the PEITC released being diluted, then, in that solution. It is probable that the 
acetic acid reacted with the derivatization reagents, considering that when the sample (PEITC released in 
10% acetic acid) was added to the derivatization solution, it became opaque. The low rate of impregnation 
may be explained also by stronger interactions of the drug for the solvent (carbon dioxide) than with the 
polymeric matrix. According to Diankov and co-workers, the interactions between the solute and the 
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carbon dioxide molecules increase at higher densities (or higher temperatures) and can diminish the 
bonding forces between the solute and the matrix (Diankov et al, 2007).  
Therefore it is necessary to optimize not only the impregnation method, but also the downstream 
characterization step, focusing on the payload release method. Nevertheless, for the results presented, the 
SD method was more efficient than the RD. These results contradict the ones of Yokozaki et workers, that 
shows otherwise: the high depressurization rate results in low impregnation rates - although Yokozaki 
work is not entirely comparable as the depressurization rate in the present work is much higher than the 
ones described in literature (Yokozaki et al, 2015).  It is thought that the extremely high depressurization 
rate lead to the precipitation and deposition of PEITC, making the solute to be laying on the particle 
















4. Conclusion and Future Work 
The main goal of this study, which was to achieve in vivo release phase and to compare the uptake of 
some encapsulated natural extracts, was not achieved. However, some important conclusions were made 
during this project regarding the preparation and characterization of the synthesized particles. Two 
synthesis methods and three encapsulation methods were tested: inverse microemulsion and spray drying 
technique were used to synthetize the particles and during the synthesis process, the encapsulation also 
took place. Additionally, impregnation by supercritical CO2 was also used as an encapsulation method. 
Inverse microemulsion method is a very good synthesis method, according to the results. Through this 
method it is possible to control the size, by changing the time of reaction, and to have mostly 
monodisperse particles. These particles can respond effectively to external stimuli, namely pH, due to the 
presence of ionizable groups capable of reacting with surrounding medium. It was not possible to 
calculate the encapsulation or liberation rate, due to the difficulty of destroying the particles with methods 
that would not affect or react with the payload. The weak point of this method is the demand for organic 
solvents for its development. This weak point is overcome with the second synthesis method: the spray 
drying.  
Spray-drying technology offers the potential to incorporate a range of excipients into the formulation to be 
spray-dried, and provides a good control over particle size, particle morphology and microsphere density.  
It is a very good and effective method, easy and quick to perform, as the solution to be spray dried is 
prepared in about one hour, and the particles can be obtained in the same day, although, is this case, the 
particles were obtained on the following day. The non-use of organic solvents in a tremendous asset, it is 
an alternative, cost-effective and, at the same time, safe and environmentally sound particle production 
method. These green methodologies help to reduce the margin of error, as they assure, in in vitro studies, 
that the positive results (in this case, the CRC cells death) are due to the designed mechanisms, and not 
because of some vestigial organic solvent that may have been not entirely withdrawn. The particles 
obtained through this method were also stimuli responsive and highly monodisperse. 
The last encapsulation method is the impregnation by CO2. This methodology did not present a good 
result and it requires optimization both of the synthesis and the downstream encapsulation rate estimate. In 
this work, the determination of that rate was performed by derivatization, that later showed to be very 
inaccurate due to the solvent in which the PEITC was dissolved being incompatible with derivatization 
reagents. Another method that can be tested to proceed to this calculation is the HPLC analysis. It can be 




These particles are meant to be ingested, after being entrapped inside a Eudragit® L100 or Eudragit®  
S100  blended capsule, as means of treating CRC. Khan studied different Eudragit®  L100/Eudragit S100 
combinations in vitro, and observed that the release profile could be changed by changing the ratio 
between these two polymers, leading to a considerable flexibility in choosing the delivery site within the 
intestinal region, better than Eudragit®  L100 or Eudragit®  S100 alone (Khan et al., 2000; Tirpude and 
Puranik, 2011). Eudragit coated formulations stand as the most commonly used synthetic polymers. Many 
colon specific delivery systems (CSDS) have one layer of Eudragit® to protect the payload from acid 
degradation in the stomach, and another to perform colon specific release. In addition, these particles 
could be administrated through rectal route throughout the use of enemas or suppositories, in case of 
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6.1 - DETERMINATION OF ISOTHIOCYANATES (ITCS) CONTENT 
 
Adapted from Zhang et al 1992 
Method: 1,2-Benzenedithiole-Based Cyclocondensation Assay  
Principle of the assay: utilizes 1,2-benzenedithiol as the vicinal dithiol reagent and measures the reaction 
product, 1,3-benzodithiole-2-thione, spectroscopically (λmax = 365 nm) . The method can be used to 
measure 1 nmol or less of pure isothiocyanates or in crude mixtures. 
Experimental procedure 
1) In 7 mL screw-top glass vials add: 
o 900 µL of 100 mM potassium phosphate buffer 
o 900 µL of methanol 
o 100 µL of sample (Blank, ITC Standard (PITC/ PEITC) or extract) 
o 100 µL of 80 mM 1,2-Benzenedithiole (the reaction initiate after 1,2-Benzenedithiole addition) 
 
2) Heat the vials at 65ºC during 2 hours in a water bath 
3) Cool at room temperature. 
4) Read the absorbance at 365 nm. 
Solutions Preparation 
a) Potassium phosphate buffer (100 mM; pH  8.5) 
Prepare two stock solutions: 
Stock A (1M of KH2PO4): weight 6.8 g and add 50 mL of H20dd 
Stock B (1M of K2HPO4): weight 8.71 g and add 50 mL of H20dd 
 
- To a 200 mL of H20dd add: 1,5 mL of Stock A and 23,5 mL of Stock B 
- Homogenize the solution and adjust the pH to 8.5 with a solution of KOH 




b) 1,2-Benzenedithiole (BDT; 80 mM; ref: 270865-500mg Sigma) 
- Stored at 4ºC (Lab 7.18A) 
- Count the number of glass vials that you will use: for each vial is added 100 µL of BDT 
- For example, for 5 mL of BDT 80 mM,  weight 56.896 mg and add 5  mL of MeOH  
(MW =142. 24 g/mol) 
- Note: the melting point of BDT is very low (22-24ºC). Be fast to avoid BDT melting. 
 
c) Phenethyl Isothiocyanate (sigma) 
- Stored at room temperature on the shelf of NutraBrass in lab 7.04 
- Prepare a stock solution of 0.1 M of phenyl ITC: 12.2 µL of ITC + 987.8 µL of MeOH 
- Dilute the stock solution (0.1M) for a 1000 µM phenyl ITC solution: 10 µL of ITC (0.1M) + 990 
µL of MeOH 
- Use the 1000 µM phenyl ITC solution to make a standard curve: 0, 40, 80, 160, 320, 640 µM 
 
Standard Curve: 
 640 µM: 360 µL MeOH + 640 µL 1000 µM phenyl ITC solution 
 320 µM: 500 µL MeOH + 500 µL 640 µM 
 160 µM: 500 µL MeOH + 500 µL 320 µM 
 80 µM: 500 µL MeOH + 500 µL 160 µM 
 40 µM: 500 µL MeOH + 500 µL 80 µM 
 0 µM: only MeOH 
 
 
 
